New insights into mineral and skeletal regulation by active forms of vitamin D.

New insights into mineral and skeletal regulation by active forms of vitamin D.
复制标题

关于活性维生素 D 形式对矿物质和骨骼调节的新见解。

DOI:
10.1038/sj.ki.5000091
复制
发表时间:
2006
影响因子:
19.6
通讯作者:
Goltzman,D
Goltzman,D
中科院分区:
医学1区
文献类型:
--
作者:
Hendy,GN;Hruska,KA;Mathew,S;Goltzman,D

文献摘要

参考文献

被引文献

相似文献

最近使用遗传方法对小鼠进行的研究揭示了1,25-二羟基维生素D(1,25(OH)2D)和维生素D受体(VDR)在骨骼和矿物质稳态中的生理作用,以及它们与钙的相互作用。这些在靶向缺失25-羟基维生素D-1 α-羟化酶(1 α(OH)酶)和VDR或双突变体的小鼠中进行的研究表明,钙在抑制甲状旁腺激素分泌和增强骨矿化方面具有独立作用,但钙和1,25(OH)2D在抑制甲状旁腺生长和软骨生长板正常发育方面具有重叠作用。然而,1,25(OH)2D/VDR系统在增强肠钙吸收和最佳增加骨细胞活化方面是必不可少的。此外,1,25(OH)2D/VDR系统对骨具有重要的合成代谢作用,因此确定了该系统在骨转换中的双重作用。这些研究揭示了维生素D/VDR系统的功能,这些功能与肾性骨病,特别是粘连性骨病的病理生理学的新概念以及维生素D活性形式的新类似物的开发有关,其具有更低的钙离子活性和更大的骨骼合成代谢作用。
Recent studies in mice using genetic approaches have shed new light on the physiological effects of 1,25-dihydroxyvitamin D (1,25(OH)2D) and the vitamin D receptor (VDR) in skeletal and mineral homeostasis, and on their interaction with calcium. These studies in mice with targeted deletion of the 25-hydroxyvitamin D-1α-hydroxylase (1α(OH)ase), and of the VDR or of double mutants, have shown the discrete effects of calcium in inhibiting parathyroid hormone secretion and in enhancing bone mineralization, but overlapping effects of calcium and 1,25(OH)2D on inhibiting parathyroid growth and on normal development of the cartilaginous growth plate. The 1,25(OH)2D/VDR system is essential, however, in enhancing intestinal calcium absorption and in optimally increasing osteoclastic activation. In addition, the 1,25(OH)2D/VDR system has important anabolic effects on bone, thus defining a dual role for this system in bone turnover. These studies are revealing functions of the vitamin D/VDR system which have relevance for new concepts of the pathophysiology of renal bone disease and, in particular, of the adynamic bone disorder, and for the development of new analogs of the active form of vitamin D, which have less calcemic activity and greater skeletal anabolic effects.
DOI: --
发表时间: 1993-06
期刊: Journal of the American Society of Nephrology : JASN
影响因子: --
作者:
R. Mathias;I. Salusky;W. Harman;A. Paredes;J. Emans;G. Segre;W. Goodman
通讯作者: R. Mathias;I. Salusky;W. Harman;A. Paredes;J. Emans;G. Segre;W. Goodman
1,25-(OH)2D3 的新类似物 19-NOR-1,25-(OH)2D2 可抑制尿毒症大鼠的血清 PTH 和甲状旁腺生长,而不升高肠道维生素 D 受体含量。
DOI: 10.1016/s0272-6386(97)90571-0
发表时间: 1997
期刊: American journal of kidney diseases : the official journal of the National Kidney Foundation
影响因子: --
作者:
Takahashi,F;Finch,JL;Denda,M;Dusso,AS;Brown,AJ;Slatopolsky,E
通讯作者: Slatopolsky,E
DOI: 10.1681/asn.2007080854
发表时间: 2008-02-01
影响因子: 13.6
作者:
Moe, Sharon M.;Chen, Neal X.
通讯作者: Chen, Neal X.
用低剂量 1,25(OH)2D3 治疗透析前慢性肾功能衰竭的继发性甲状旁腺功能亢进:体液和组织形态学结果。
DOI: --
发表时间: 1986
期刊: Mineral and Electrolyte Metabolism
影响因子: --
作者:
G. Coen;S. Mazzaferro;E. Bonucci;P. Ballanti;C. Massimetti;G. Donato;A. Landi;A. Smacchi;C. Della Rocca;G. Cinotti
通讯作者: G. Cinotti
透析患者口服、静脉注射和腹膜内给药后骨化三醇的生物利用度。
DOI: --
发表时间: 1988
期刊:
影响因子: --
作者:
I. Salusky;W. Goodman;Keith C. Norris;R. Horst;R. Fine;J. Coburn
通讯作者: J. Coburn